Comparative Evaluation of Two Severe Acute Respiratory Syndrome (Sars) Vaccine Candidates in Mice Challenged with Sars Coronavirus.
From: University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada.
The Journal of general virology
- Publish Date: Mar 2006
- ISSN: 0022-1317
- Volume: 87
- Issue: Pt 3
- Pages: 641-50
- Medium: Print
- Language: English
- Citation (JAMA): See Raymond H, Zakhartchouk Alexander N, Petric Martin, et al. Comparative Evaluation of Two Severe Acute Respiratory Syndrome (Sars) Vaccine Candidates in Mice Challenged with Sars Coronavirus.. J. Gen. Virol. Mar 2006;87:641-50
Abstract
Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by beta-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with cellular immune responses as measured by gamma interferon secretion by mouse splenocytes. Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally or intramuscularly were significantly lower than those induced by the WKV vaccine. However, Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection.
Mesh Headings (Keywords): Administration, Intranasal, Animals, Antibodies, Viral, Antibody Specificity, Disease Models, Animal, Drug Evaluation, Preclinical, Female, Immunoglobulin A, Injections, Intramuscular, Injections, Subcutaneous, Membrane Glycoproteins, Mice, Neutralization Tests, Nucleocapsid Proteins, SARS Virus, Severe Acute Respiratory Syndrome, Vaccination, Vaccines, DNA, Viral Envelope Proteins, Viral Vaccines
Check for Full Text / PubMed Unique Identifier (PMID): 16476986
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.